Genflow to Attend Healthcare Conference
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference LONDON, UK / ACCESS Newswire / December 11, 2025 /...
Clinical Trial
ECOG-ACRIN and Caris Life Sciences unveil first findings from a multi-year collaboration to advance AI-powered multimodal tools for breast cancer recurrence risk stratification
New AI models integrating imaging, clinical, and molecular data from the TAILORx tissue biorepository show stronger prognostic performance than current...
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),...
Sentynl Selects myTomorrows to Lead Managed Access Program
Reinforcing its commitment to rare disease treatment access, Sentynl is transitioning its program to myTomorrows patient-centric platform. AMSTERDAM, Dec. 10, 2025...
Spectrum Science Unifies Portfolio Companies Under Single Brand, Reinforcing Power of Integrated Strategic Platform
Connected Brand Identity Simplifies Access to Innovative, Agile Solutions that Drive Momentum for Companies in the Health and Life Science...
Veritiv Expands Its TempSafe® Portfolio With the Industry’s First Curbside-Recyclable Pallet Shipper for Biopharmaceutical Cold Chain
ATLANTA, Dec. 10, 2025 /PRNewswire/ -- Veritiv Operating Company, a leader in specialty packaging distribution, facility solutions and print products and...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
Roche’s giredestrant reduced risk of invasive disease recurrence or death by 30% in ER-positive early-stage breast cancer
Giredestrant is the only oral SERD to show superior invasive disease-free survival in the adjuvant setting, marking the first significant...
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility
Developed and evaluated specifically for women, DARE to PLAY™ Sildenafil Cream is a first-of-its-kind female arousal cream, a non-hormonal topical...
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
VTP-1000, an antigen-specific immunotherapy to treat celiac disease, showed a dose-dependent pharmacological effect in the SAD portion of the trialVTP-1000...
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
Fulcrum Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering of Common Stock and Pre-Funded Warrants
CAMBRIDGE, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on...
Avance Clinical Launches Diversity in STEM Scholarships Across Australia and North America
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch...
Avance Clinical Launches Diversity in STEM Scholarships Across Australia and North America
ADELAIDE, Australia, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Avance Clinical, the award-winning global CRO for biotechs, has announced the launch...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors
MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H...
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ...